(HHT) |
| 0 (0%) 05-30 00:48 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 44.91 |
| Resistance 1: | 38.45 |
| Pivot price: | 37.19 |
| Support 1: | 36.96 |
| Support 2: | 36.03 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 2.630 |
| Book Value | 36.420 |
| PEG Ratio | 0.61 |
| Gross Profit | 21.527 |
| Profit Margin (%) | 12.76 |
| Operating Margin (%) | 16.89 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 7.6 |
Company news
Tue, 26 May 2026
Cure HHT Announces Historic Federal Research Designation for Hereditary Hemorrhagic Telangiectasia - The National Law Review
Wed, 08 Apr 2026
Advocating for Expanded Access to Care: Miller School Leaders Take HHT Awareness to Capitol Hill - University of Miami
Wed, 01 Apr 2026
Bevacizumab as Rescue Therapy for GI Bleeding in Hereditary Hemorrhagic Telangiectasia - Cureus
Mon, 23 Mar 2026
Left Atrial Appendage Occlusion in Patients With Hereditary Hemorrhagic Telangiectasia and Atrial Fibrillation - JACC Journals
Thu, 05 Mar 2026
Atavistik bags another $40M to advance drug for rare vascular disease - FirstWord Pharma
Wed, 25 Feb 2026
Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
